Liver fat accumulation is associated with circulating PCSK9

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms

(2016) Hagai Tavori et al.   CARDIOVASCULAR RESEARCH

Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

(2016) Nicola Ferri et al.   Translational Research

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

(2015) Paola Dongiovanni et al.   HEPATOLOGY

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line

(2015) Massimiliano Ruscica et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients

(2015) Ymène Nekaies et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Statin use and non-alcoholic steatohepatitis in at risk individuals

(2015) Paola Dongiovanni et al.   JOURNAL OF HEPATOLOGY

The Effects of Estrogen on Serum Level and Hepatocyte Expression of PCSK9

(2015) Wen Guo et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

PCSK9 and lipid lowering drugs

(2014) Yuan-Lin Guo et al.   CLINICA CHIMICA ACTA

Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

(2014) Moumita Ghosh et al.   JOURNAL OF LIPID RESEARCH

Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment

(2014) Christian Werner et al.   VASCULAR PHARMACOLOGY

The burden of liver disease in Europe: A review of available epidemiological data

(2013) Martin Blachier et al.   JOURNAL OF HEPATOLOGY

Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects

(2013) Chan Joo Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

(2013) Bertrand Cariou et al.   Nutrition & Metabolism

PNPLA3 I148M polymorphism and progressive liver disease

(2013) Paola Dongiovanni   WORLD JOURNAL OF GASTROENTEROLOGY

Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects

(2012) R Rametta et al.   INTERNATIONAL JOURNAL OF OBESITY

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis

(2012) Giovanni Musso et al.   PROGRESS IN LIPID RESEARCH

Thiazolidinediones and PPARγ agonists: time for a reassessment

(2012) Bertrand Cariou et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure–function relation to therapeutic inhibition

(2011) G. Tibolla et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

(2010) Giovanni Musso et al.   HEPATOLOGY

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Short telomeres are a risk factor for idiopathic pulmonary fibrosis

(2008) J. K. Alder et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA